Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SBRT + Nab-Paclitaxel + Toripalimab in HR+/HER2- Breast Cancer
NCT06914440Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in breast cancer, sponsored by Xijing Hospital. Primary endpoint: Total pathologic complete response rate at 4 months. Started Jun 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06914440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914440.